{"id":142,"date":"2013-10-16T17:04:21","date_gmt":"2013-10-16T17:04:21","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=142"},"modified":"2017-08-21T13:09:50","modified_gmt":"2017-08-21T13:09:50","slug":"primary-care-corner-with-geoffrey-modest-update-on-oi-prevention-in-hiv","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2013\/10\/16\/primary-care-corner-with-geoffrey-modest-update-on-oi-prevention-in-hiv\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest: Update on OI prevention in HIV"},"content":{"rendered":"<p>recent update on prevention and treatment of opportunistic infections in HIV infected adolescents and adults.<\/p>\n<p>&nbsp;<\/p>\n<p>reference: Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health [trunc]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2013 Jul 8.<\/p>\n<p>&nbsp;<\/p>\n<p>on-line access: \u00a0<a href=\"http:\/\/www.guideline.gov\/content.aspx?f=rss&amp;id=45359&amp;osrc=12\">http:\/\/www.guideline.gov\/content.aspx?f=rss&amp;id=45359&amp;osrc=12<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>some new info incorporated. \u00a0the guidelines provide very specific recommendations, without a lot of text, for the myriad of HIV-related infections. a couple of notable changes:<\/p>\n<p>&nbsp;<\/p>\n<p>&#8211;hep b. vaccination is as per non-HIV infected. important to check post-vaccination HbsAb to assess response. if non-responder, can wait til increase of CD4 if low, and then repeat; can give another series of vaccines; can give double dose vaccines (there have been a couple of articles in past year showing increased immunogenicity of the double-dose vaccine in HIV patients, so this is my preferred approach)<\/p>\n<p>&nbsp;<\/p>\n<p>&#8211;hep c. includes use of protease inhibitors (boceprevir, telaprevir) along with interferon\/ribivarin<\/p>\n","protected":false},"excerpt":{"rendered":"<p>OI prevention update in HIV [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2013\/10\/16\/primary-care-corner-with-geoffrey-modest-update-on-oi-prevention-in-hiv\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-142","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=142"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/142\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}